Covered recipient · General Payments record
DONNA G CRESS
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner Adult Health
General Payments · PY2021–2024
$1,210.72
- Reported across 53 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $552.83 | 19 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| REVANCE THERAPEUTICS, INC. | $273.28 | 7 |
| ABBVIE INC. | $264.09 | 11 |
| Galderma Laboratories, L.P. | $15.46 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (19)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $7.49 | 02/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966601 | CMS |
| ABBVIE INC. | $11.55 | 02/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966603 | CMS |
| ABBVIE INC. | $63.49 | 02/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966605 | CMS |
| ABBVIE INC. | $12.86 | 03/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966607 | CMS |
| ABBVIE INC. | $14.32 | 05/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966609 | CMS |
| ABBVIE INC. | $6.26 | 07/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966611 | CMS |
| ABBVIE INC. | $15.23 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966613 | CMS |
| ABBVIE INC. | $4.43 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966615 | CMS |
| ABBVIE INC. | $16.40 | 09/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966617 | CMS |
| ABBVIE INC. | $11.45 | 11/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966619 | CMS |
| ABBVIE INC. | $100.61 | 11/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106966621 | CMS |
| Galderma Laboratories, L.P. | $15.46 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145351799 | CMS |
| REVANCE THERAPEUTICS, INC. | $30.62 | 02/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147937293 | CMS |
| REVANCE THERAPEUTICS, INC. | $29.68 | 04/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147937295 | CMS |
| REVANCE THERAPEUTICS, INC. | $20.95 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147937297 | CMS |
| REVANCE THERAPEUTICS, INC. | $39.41 | 08/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147937299 | CMS |
| REVANCE THERAPEUTICS, INC. | $80.23 | 08/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147937301 | CMS |
| REVANCE THERAPEUTICS, INC. | $54.54 | 09/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147937303 | CMS |
| REVANCE THERAPEUTICS, INC. | $17.85 | 09/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1147937305 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.